(Q37874146)

24 August 2017

Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects (English)

1 reference

24 August 2017

1

Mark Pimentel

1 reference

24 August 2017

Walter Morales

2

1 reference

24 August 2017

Kathleen Chua

3

1 reference

24 August 2017

Gillian Barlow

4

1 reference

24 August 2017

Stacy Weitsman

5

1 reference

24 August 2017

Gene Kim

6

1 reference

24 August 2017

Meridythe M Amichai

7

1 reference

24 August 2017

Venkata Pokkunuri

8

1 reference

24 August 2017

Emily Rook

9

1 reference

24 August 2017

Ruchi Mathur

10

1 reference

24 August 2017

Zachary Marsh

11

1 reference

24 August 2017

11 May 2011

1 reference

Digestive Diseases and Sciences

24 August 2017

1 reference

24 August 2017

56

1 reference

24 August 2017

7

1 reference

24 August 2017

2067-2072

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-011-1728-5

24 August 2017

0 references

cites work

Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Rifaximin: in vitro and in vivo antibacterial activity--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Abnormal breath testing in IBS: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21559740

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21559740

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21559740

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10620-011-1728-5

1 reference

24 August 2017

1 reference